ARTICLE | Product Development
Innovation in autoimmune CAR Ts doesn’t stop at CD19
Dual targeting, allogeneic designs and novel targets are all under investigation to help CAR T cells reach more autoimmune patients
October 5, 2023 9:18 PM UTC
Though the use of CAR T cells in autoimmunity is still in its infancy, the field is already charging ahead of the easiest target, CD19, to explore new targets and technologies that could broaden the autoimmune indications addressable by the modality.
CD19 is the CAR T target that’s been most extensively validated, both clinically and commercially, in cancer. There’s also a solid scientific case and highly convincing early clinical data for the target in this modality in autoimmunity, making it a logical choice for gaining proof of concept in the new use cases. ...